Literature DB >> 24337750

Lack of galactosylation enhances the pathogenic activity of IgG1 but Not IgG2a anti-erythrocyte autoantibodies.

Kiyoaki Ito1, Jun-ichi Furukawa, Kazunori Yamada, Ngoc Lan Tran, Yasuro Shinohara, Shozo Izui.   

Abstract

IgG bears asparagine-linked oligosaccharide side chains in the Fc region. Variations in their extent of galactosylation and sialylation could modulate IgG Fc-dependent effector functions, and hence Ab activity. However, it has not yet been clarified whether the pathogenic potential of IgG autoantibodies is consistently enhanced by the absence of galactose residues per se or the lack of terminal sialylation, which is dependent on galactosylation. Moreover, it remains to be defined whether the increased pathogenicity of agalactosylated IgG is related to activation of the complement pathway by mannose-binding lectin, as suggested by in vitro studies. Using a murine model of autoimmune hemolytic anemia, we defined the contribution of galactosylation or sialylation to the pathogenic activity of IgG1 and IgG2a anti-erythrocyte class-switch variants of 34-3C monoclonal autoantibody. We generated their degalactosylated or highly sialylated glycovariants and compared their pathogenic effects with those of highly galactosylated or desialylated counterparts. Our results demonstrated that lack of galactosylation, but not sialylation, enhanced the pathogenic activity of 34-3C IgG1, but not IgG2a autoantibodies. Moreover, analysis of in vivo complement activation and of the pathogenic activity in mice deficient in C3 or IgG FcRs excluded the implication of mannose-binding lectin-mediated complement activation in the enhanced pathogenic effect of agalactosylated IgG1 anti-erythrocyte autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337750     DOI: 10.4049/jimmunol.1302488

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases.

Authors:  Mirna Šimurina; Noortje de Haan; Frano Vučković; Nicholas A Kennedy; Jerko Štambuk; David Falck; Irena Trbojević-Akmačić; Florent Clerc; Genadij Razdorov; Anna Khon; Anna Latiano; Renata D'Incà; Silvio Danese; Stephan Targan; Carol Landers; Marla Dubinsky; Dermot P B McGovern; Vito Annese; Manfred Wuhrer; Gordan Lauc
Journal:  Gastroenterology       Date:  2018-01-06       Impact factor: 22.682

Review 2.  Immunoglobulin Glycosylation Effects in Allergy and Immunity.

Authors:  Alexandra Epp; Kathryn C Sullivan; Andrew B Herr; Richard T Strait
Journal:  Curr Allergy Asthma Rep       Date:  2016-11       Impact factor: 4.806

3.  Immunoglobulin G Glycosylation Changes in Aging and Other Inflammatory Conditions.

Authors:  Fabio Dall'Olio; Nadia Malagolini
Journal:  Exp Suppl       Date:  2021

4.  Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome.

Authors:  Irena Trbojević Akmačić; Nicholas T Ventham; Evropi Theodoratou; Frano Vučković; Nicholas A Kennedy; Jasminka Krištić; Elaine R Nimmo; Rahul Kalla; Hazel Drummond; Jerko Štambuk; Malcolm G Dunlop; Mislav Novokmet; Yurii Aulchenko; Olga Gornik; Harry Campbell; Maja Pučić Baković; Jack Satsangi; Gordan Lauc
Journal:  Inflamm Bowel Dis       Date:  2015-06       Impact factor: 5.325

5.  Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid.

Authors:  Manfred Wuhrer; Maurice H J Selman; Liam A McDonnell; Tania Kümpfel; Tobias Derfuss; Mohsen Khademi; Tomas Olsson; Reinhard Hohlfeld; Edgar Meinl; Markus Krumbholz
Journal:  J Neuroinflammation       Date:  2015-12-18       Impact factor: 8.322

6.  Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn.

Authors:  Rick Kapur; Luciana Della Valle; Myrthe Sonneveld; Agnes Hipgrave Ederveen; Remco Visser; Peter Ligthart; Masja de Haas; Manfred Wuhrer; C Ellen van der Schoot; Gestur Vidarsson
Journal:  Br J Haematol       Date:  2014-06-07       Impact factor: 6.998

7.  Patients with IgG1-anti-red blood cell autoantibodies show aberrant Fc-glycosylation.

Authors:  Myrthe E Sonneveld; Masja de Haas; Carolien Koeleman; Noortje de Haan; Sacha S Zeerleder; Peter C Ligthart; Manfred Wuhrer; C Ellen van der Schoot; Gestur Vidarsson
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

8.  Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis.

Authors:  Yuhsuke Ohmi; Wataru Ise; Akira Harazono; Daisuke Takakura; Hidehiro Fukuyama; Yoshihiro Baba; Masashi Narazaki; Hirofumi Shoda; Nobunori Takahashi; Yuki Ohkawa; Shuting Ji; Fumihiro Sugiyama; Keishi Fujio; Atsushi Kumanogoh; Kazuhiko Yamamoto; Nana Kawasaki; Tomohiro Kurosaki; Yoshimasa Takahashi; Koichi Furukawa
Journal:  Nat Commun       Date:  2016-04-05       Impact factor: 14.919

9.  Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.

Authors:  Tetyana Dashivets; Marco Thomann; Petra Rueger; Alexander Knaupp; Johannes Buchner; Tilman Schlothauer
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

10.  Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.

Authors:  Gina-Maria Lilienthal; Johann Rahmöller; Janina Petry; Yannic C Bartsch; Alexei Leliavski; Marc Ehlers
Journal:  Front Immunol       Date:  2018-05-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.